Latest Leadership Updates News

Compumedics reported a record $60.3 million in FY26 revenue, driven by an 18% year-on-year increase and a 70% jump in SaaS recurring revenues from Somfit and Nexus 360. The company resolved supply chain disruptions and targets faster EBITDA growth in FY27.

Northern Star Resources has met its revised FY26 gold sales guidance with a strong June quarter performance and remains on track with the KCGM mill expansion. The company also announced the appointment of Suresh Vadnagra as its next CEO, effective October 2026.

Salt Listed Funds released its 2026 annual report highlighting governance changes, investment policy updates including Treasury Units and Carbon-Related Businesses, and a notable decline in the Carbon Fund’s unit price over the year.

Collins Foods delivered record FY26 revenue and underlying profit, declaring a 15c fully franked final dividend while exiting Taco Bell to sharpen focus on KFC expansion in Australia and Europe.

Stride Property Group posted a 44% jump in FY26 profit after tax to $31.3 million, driven by strategic portfolio moves, management fee growth, and sustainability progress. The group maintained an 8.0cps dividend amid a $1.4 billion diversified property portfolio and a strong balance sheet.

Little Green Pharma (ASX:LGP) posted a 15.3% revenue increase to AUD 42.5 million in FY2026, driven by European market expansion, yet recorded a $1.4 million loss after tax impacted by significant inventory write-downs.

Ventia Services Group reported a strong FY25 with revenue of $6.1 billion and 13% NPATA growth, while CEO Dean Banks announced his planned departure later this year. The company reaffirmed its FY26 guidance and highlighted growth opportunities in Defence, Digital Infrastructure, Energy, and Water.

Ausgold Limited has promoted Ben Stockdale from CFO to CEO and appointed Reece Olney as GM Operations, reinforcing its leadership as the Katanning Gold Project approaches a final investment decision.

The Smart US 500 ETF reported a near-billion-dollar fund size with a 5-year average annual return of 14.14% after fees and tax, maintaining a high-risk profile and low management fees of 0.34%.

Clarity Pharmaceuticals’ Phase II Co-PSMA trial confirms its Cu-SAR-bisPSMA PET imaging detects more than twice the prostate cancer lesions versus standard care, driving patient management changes. Phase III AMPLIFY recruitment closes, manufacturing deals inked, and cash sits near $198 million.

Bio-Gene Technology is progressing critical toxicology studies for Flavocide with a targeted APVMA submission in March 2027, while forging a strategic partnership to launch Qcide insecticides in Japan by late 2026.

Felix Group Holdings reported a 47% surge in total ARR to $12.7 million in Q3 FY26, driven by the Nexvia acquisition and enterprise expansion. The company is progressing AI platform enhancements and completed a key leadership renewal with new Chairman and CEO appointments.